Original Post: https://greatawakening.win/p/140IiftB0l/whoa--man-who-traveled-to-space-/

Medidata Supports Moderna’s COVID-19 Vaccine Clinical Trials with Rave Clinical Cloud Platform

https://en.wikipedia.org/wiki/Medidata_Solutions

Medidata Solutions is an American technology company that develops and markets software as a service (SaaS) for clinical trials. These include protocol development, clinical site collaboration and management; randomization and trial supply management; capturing patient data through web forms, mobile health (mHealth) devices, laboratory reports, and imaging systems; quality monitor management; safety event capture; and monitoring and business analytics. Headquartered in New York City, Medidata has locations in China, Japan, Singapore, South Korea, the United Kingdom, and the United States.

Medidata's customers include pharmaceutical, biotechnology, medical device, and diagnostic companies; academic and government institutions; contract research organizations; and other life sciences organizations around the world that develop and bring medical therapies and products to market

https://www.nasdaq.com/press-release/medidata-supports-modernas-covid-19-vaccine-clinical-trials-with-rave-clinical-cloud

Medidata, a Dassault Systèmes company, the global leader in creating end-to-end solutions supporting the entire clinical trial process today announced that it is collaborating with Moderna, Inc. (Nasdaq: MRNA) to support clinical trials of mRNA-1273, Moderna’s COVID-19 vaccine candidate.

Medidata’s suite of technologies is supporting the advancement of Moderna’s mRNA-1273 clinical trials, including the Phase 3 trial, which is expected to enroll 30,000 participants. The Medidata and Moderna teams are moving forward with the speed and urgency necessitated by the global pandemic, using Medidata’s innovative and scalable cloud platform for clinical development.

This clinical trial is one of the largest ever to incorporate data capture directly from participants, decreasing the need for office visits. The “virtualization” of the study allows participants to use their own devices if they so choose, easing the burden of having to carry around a separate, provisioned device.

“We are proud to be working with Moderna on these breakthrough trials, which are so important to medical science and the health of our global society,” said Tarek Sherif, co-founder and co-CEO, Medidata. “The extensive partnership we’ve built together over many years is allowing us to support these critical clinical studies. Clearly, the faster we can arrive at answers, the better it will be for everyone, everywhere.”